Analyst Price Targets — SRTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:57 pm | Anthony Vendetti | Maxim Group | $6.00 | $3.91 | TheFly | Sensus Healthcare price target lowered to $6 from $8 at Maxim |
| May 13, 2024 7:17 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $5.56 | StreetInsider | Sensus Healthcare (SRTS) PT Raised to $10 at H.C. Wainwright |
| May 6, 2022 12:12 pm | — | H.C. Wainwright | $16.00 | $7.71 | Benzinga | HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $16 |
Latest News for SRTS
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and connectivity solution intended to expand advanced operating capabilities across the Company's SRT-100™ system…
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial…
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025. Highlights include the following: Revenues were $4.9 million for the quarter and…
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRTS.
U.S. House Trading
No House trades found for SRTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.